<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00609739</url>
  </required_header>
  <id_info>
    <org_study_id>1999LS032</org_study_id>
    <secondary_id>UMN-MT1999-08</secondary_id>
    <secondary_id>9906M07303</secondary_id>
    <nct_id>NCT00609739</nct_id>
  </id_info>
  <brief_title>Cytosine Arabinoside and Mitoxantrone for Patients With Juvenile Myelomonocytic Leukemia Receiving Repeat Stem Cell Transplantation</brief_title>
  <official_title>Cytosine Arabinoside and Mitoxantrone for Patients With Juvenile Myelomonocytic Leukemia Receiving Repeat Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Giving chemotherapy drugs, such as cytarabine and mitoxantrone, before a donor
      stem cell transplant helps stop the growth of cancer cells and helps stop the patient's
      immune system from rejecting the donor's stem cells. When certain stem cells from a donor are
      infused into the patient they may help the patient's bone marrow make stem cells, red blood
      cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can
      make an immune response against the body's normal cells. Giving cyclosporine, methotrexate,
      and methylprednisolone before or after transplant may stop this from happening.

      PURPOSE: This phase I/II trial is studying the side effects and best way to give high-dose
      cytarabine together with mitoxantrone in treating patients with juvenile myelomonocytic
      leukemia undergoing a second donor stem cell transplant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To determine the incidence of 1-year disease-free survival in patients with juvenile
           myelomonocytic leukemia and who is undergoing a repeat stem cell transplantation.

      Secondary

        -  To evaluate the incidence of regimen-related toxicity.

        -  To evaluate the incidence of acute and chronic graft-versus-host-disease.

        -  To evaluate the incidence of relapse.

      OUTLINE:

        -  Preparative cytoreductive therapy: Patients receive high-dose cytarabine IV over 2 hours
           on days -9 to -4 and mitoxantrone hydrochloride IV over 30 minutes on days -9 to -7.

        -  Allogeneic hematopoietic stem cell transplantation (HSCT): Patients undergo HSCT on day
           0. Patients undergoing umbilical cord blood transplantation receive methylprednisolone
           (as graft failure prophylaxis) IV twice daily on days 5 to 19 followed by a taper every
           other day thereafter until day 25.

        -  Graft-versus-host-disease (GVHD) prophylaxis: Patients receive cyclosporine IV over 2
           hours every 8-12 hours or orally twice daily beginning on day -3 and continuing until
           day 50, followed by a taper to day 90, in the absence of GVHD. Patients undergoing
           nongenotypically identical bone marrow transplantation also receive methotrexate IV on
           day 1 beginning 24 hours after completion of stem cell infusion and on days 3, 6, and
           11.

        -  Post-transplantation isotretinoin therapy: Patients receive oral isotretinoin once daily
           beginning on day 60 and continuing until 1 year after HSCT.

      Patients undergo bone marrow sample collection on day 21, day 60, day 100, at 6 months, and
      at 1 year for chimerism studies. Patients also undergo blood sample collection periodically
      to monitor peripheral blood counts for immune reconstitution.

      After completion of study treatment, patients are followed on day 21, day 100, at 6 months,
      and at 1 year.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low accrual
  </why_stopped>
  <start_date>June 1999</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free Survival</measure>
    <time_frame>1 year</time_frame>
    <description>Number of patients who were free of disease and alive at 1 year.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patients With Regimen-Related Toxicity</measure>
    <time_frame>Up to 30 Days Post Study Treatment</time_frame>
    <description>Number of patients with adverse events related to treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients With Graft-Versus-Host-Disease</measure>
    <time_frame>Up to 30 Days Post Study Treatment</time_frame>
    <description>Number of patients who exhibited acute and/or chronic graft-versus-host disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients Who Relapsed</measure>
    <time_frame>1 Year</time_frame>
    <description>Number of patients whose disease relapsed.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>Cytarabine + Mitoxantrone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a phase I-II study designed to evaluate the efficacy of the administration of high dose cytosine arabinoside and mitoxantrone followed by HCT in patients with JMML who have residual disease or have relapsed after initial HCT.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
    <description>Patients will receive CSA therapy beginning on day -3, with a taper commencing on day +60 (unless GVHD) and ending on day +90. For patients &gt;40 kg with normal renal function (creatinine &lt;1.3 mg/dL), the initial dose will be 2.5 mg/kg intravenously (IV) over 2 hours every 12 hours. For children &lt;40 kg, the initial dose will be 2.5 mg/kg IV over 2 hours every 8 hours.</description>
    <arm_group_label>Cytarabine + Mitoxantrone</arm_group_label>
    <other_name>CSA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
    <description>3000 mg/m^2 intravenously (IV) over 2 hours x 2 (i.e. total 6000 mg/m^2/day) on days -9 through -4.</description>
    <arm_group_label>Cytarabine + Mitoxantrone</arm_group_label>
    <other_name>Ara-C</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <description>Patients with absolute neutrophil count (ANC) &lt;0.2 x 10^8/L on day 21 may receive G-CSF at 5 mcg/kg/day. G-CSF will be continued until ANC â‰¥2.5 x 10^8/L for two consecutive days. As the malignant cell population of JMML is known to be hypersensitive to GM-CSF, this cytokine will not be given to these patients.</description>
    <arm_group_label>Cytarabine + Mitoxantrone</arm_group_label>
    <other_name>G-CSF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <description>MTX will be administered to recipients of non-genotypically identical BMT. MTX will be administered at a dose of 15 mg/m^2 (based on adjusted ideal body weight) intravenously (IV) on day +1 and at a dose of 10 mg/m^2 IV on days +3, +6, and +11.</description>
    <arm_group_label>Cytarabine + Mitoxantrone</arm_group_label>
    <other_name>MTX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylprednisolone</intervention_name>
    <description>Recipients of UCB will receive methylprednisolone 2 mg/kg/day from day +5 to +19 at a dose of 1 mg/kg twice a day (bid) with a 10% taper every week thereafter.</description>
    <arm_group_label>Cytarabine + Mitoxantrone</arm_group_label>
    <other_name>Medrol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mitoxantrone hydrochloride</intervention_name>
    <description>10 mg/m^2 over 30 minutes intravenously (IV) on days -9 through -7.</description>
    <arm_group_label>Cytarabine + Mitoxantrone</arm_group_label>
    <other_name>Mitoxantrone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic bone marrow transplantation</intervention_name>
    <description>Donor marrow will be collected in the usual sterile manner with a collection goal of 2.0 &gt;10^8/kg recipient weight. Infused on Day 0.</description>
    <arm_group_label>Cytarabine + Mitoxantrone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>umbilical cord blood transplantation</intervention_name>
    <description>Umbilical cord blood (UCB) will be cryopreserved prior to transplantation. Cord blood units will be selected for transplantation according to current University of Minnesota Department of Blood and Marrow Transplantation Guidelines.</description>
    <arm_group_label>Cytarabine + Mitoxantrone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cis-Retinoic acid</intervention_name>
    <description>Post-Transplant Cis-Retinoic Acid (CRA) Therapy - CRA will be given at a dosage of 100 mg/m^2/day by mouth in a single daily dose starting on day +60 and continuing until 1 year after transplant.</description>
    <arm_group_label>Cytarabine + Mitoxantrone</arm_group_label>
    <other_name>isotretinoin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients age 0-18 with juvenile myelomonocytic leukemia (JMML) who have relapsed or
             have residual disease after allogeneic HCT. Residual disease is defined as failure to
             eradicate original disease without prior documentation of remission. Relapse is
             defined as reappearance of i) leukocytosis with absolute monocytosis &gt;1 x 10^8/L, ii)
             presence of immature myeloid cells in the peripheral circulation in two consecutive
             bone marrow specimens taken at least one month apart, or iii) presence of clonal
             cytogenetic abnormality. The diagnosis of relapse will be supported by the return of
             an abnormal cytogenetic marker (if present at diagnosis) or the presence of host cells
             by RFLP or other method.

          -  Patients should be at least 6 months from first hematopoietic cell transplant (HCT) if
             clinically stable. (If JMML is rapidly progressive, second HCT may be performed
             earlier).

               -  Adequate major organ function including:

                    -  Cardiac: ejection fraction â‰¥45%

                    -  Pulmonary: FEV &gt;50%, DLCO &gt;50%

               -  Renal: creatinine clearance â‰¥40 mL/min

                    -  Hepatic: no clinical evidence of hepatic failure (e.g. coagulopathy,
                       ascites)

               -  Karnofsky performance status â‰¥70% or Lansky score â‰¥50%

          -  Written informed consent.

        Exclusion Criteria:

          -  Active uncontrolled infection within one week of HCT.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margaret L. MacMillan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Masonic Cancer Center, University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Masonic Cancer Center at University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2008</study_first_submitted>
  <study_first_submitted_qc>February 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2008</study_first_posted>
  <results_first_submitted>November 22, 2011</results_first_submitted>
  <results_first_submitted_qc>January 31, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 2, 2012</results_first_posted>
  <last_update_submitted>December 3, 2017</last_update_submitted>
  <last_update_submitted_qc>December 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>juvenile myelomonocytic leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Acute</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Tretinoin</mesh_term>
    <mesh_term>Isotretinoin</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Mitoxantrone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Only 1 patient was enrolled (yr 1999) and later died (yr 2000). Study was terminated due to low accrual.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Cytarabine + Mitoxantrone</title>
          <description>Patients receive administration of high dose cytosine arabinoside and mitoxantrone followed by hematopoietic cell transplant.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cytarabine + Mitoxantrone</title>
          <description>Patients receive administration of high dose cytosine arabinoside and mitoxantrone followed by hematopoietic cell transplant.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Disease-free Survival</title>
        <description>Number of patients who were free of disease and alive at 1 year.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cytarabine + Mitoxantrone</title>
            <description>Patients receive administration of high dose cytosine arabinoside and mitoxantrone followed by hematopoietic cell transplant.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease-free Survival</title>
          <description>Number of patients who were free of disease and alive at 1 year.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients With Regimen-Related Toxicity</title>
        <description>Number of patients with adverse events related to treatment.</description>
        <time_frame>Up to 30 Days Post Study Treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cytarabine + Mitoxantrone</title>
            <description>Patients receive administration of high dose cytosine arabinoside and mitoxantrone followed by hematopoietic cell transplant.</description>
          </group>
        </group_list>
        <measure>
          <title>Patients With Regimen-Related Toxicity</title>
          <description>Number of patients with adverse events related to treatment.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients With Graft-Versus-Host-Disease</title>
        <description>Number of patients who exhibited acute and/or chronic graft-versus-host disease.</description>
        <time_frame>Up to 30 Days Post Study Treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cytarabine + Mitoxantrone</title>
            <description>Patients receive administration of high dose cytosine arabinoside and mitoxantrone followed by hematopoietic cell transplant.</description>
          </group>
        </group_list>
        <measure>
          <title>Patients With Graft-Versus-Host-Disease</title>
          <description>Number of patients who exhibited acute and/or chronic graft-versus-host disease.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients Who Relapsed</title>
        <description>Number of patients whose disease relapsed.</description>
        <time_frame>1 Year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cytarabine + Mitoxantrone</title>
            <description>Patients receive administration of high dose cytosine arabinoside and mitoxantrone followed by hematopoietic cell transplant.</description>
          </group>
        </group_list>
        <measure>
          <title>Patients Who Relapsed</title>
          <description>Number of patients whose disease relapsed.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 30 days post study treatment.</time_frame>
      <desc>Regimen related toxicity (RRT) is a concern, but because of the seriousness of relapsed JMML, a high incidence of grade III and IV RRT will be considered acceptable. No other adverse events were collected.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cytarabine + Mitoxantrone</title>
          <description>Patients receive administration of high dose cytosine arabinoside and mitoxantrone followed by hematopoietic cell transplant.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Only 1 patient was enrolled (yr 1999) and later died (yr 2000). Study was terminated due to low accrual.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Margaret MacMillan, M.D.</name_or_title>
      <organization>Masonic Cancer Center, University of Minnesota</organization>
      <phone>612-626-2778</phone>
      <email>macmi002@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

